1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH SBIR/STTR Omnibus Grant Solicitations (NCI) is a grant program from the National Cancer Institute, part of the National Institutes of Health, that funds investigator-initiated small business innovation research across a broad spectrum of health and cancer research topic areas.
The program encompassed both Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) mechanisms through Phase I (R43/R41) and Phase II (R44/R42) awards, with options for both clinical trial and non-clinical trial research.
Eligible applicants are U.S. small business concerns with research capabilities and technological expertise relevant to NIH's mission, including those majority-owned by venture capital operating companies, hedge funds, or private equity firms. Note that the legislative authority for the SBIR/STTR programs expired on October 1, 2025, and NIH currently has no active solicitations.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NCI SBIR/STTR Omnibus Grant Solicitations - NCI NIH has no active Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) solicitations because the legislative authority for the programs expired on October 1, 2025. Current recipients should direct any questions to their Program Officer. See NOT-OD-26-006 .
NCI SBIR/STTR Omnibus Grant Solicitations The Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) Omnibus Solicitations are intended to support small business innovation research across a broad spectrum of topic areas.
U.S. small businesses that have the research capabilities and technological expertise to contribute to the research and development missions of the awarding components identified in the Omnibus Solicitation are encouraged to submit investigator-initiated SBIR & STTR grant applications in response to the identified topics.
Applicants may also consider other areas of research within the mission of any of the awarding components and submit an SBIR & STTR application Small business concerns that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds and/or private equity firms continue to be eligible to apply to the CDC and NIH SBIR program and compete for up to 15% and 25% respectively of each agency's SBIR set-aside.
Omnibus Solicitation Opportunities This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.
SBIR Program: PA-24-245 (Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 SBIR Program: PA-24-246: (Clinical Trial Required) PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 STTR Program: PA-24-247 (Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 STTR Program: PA-24-248 (Clinical Trial Required) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 Online HTML Application Guide SF424 (R&R) Application Guide for SBIR/STTR Grant Applications (Version H) Annotated SF424 SBIR/STTR Form Set NIH Matchmaker - Use NIH Matchmaker to conduct keyword searches on a particular topic area to identify NIH Institutes or Centers (ICs) that have previously funded research area.
According to the current listing, eligibility includes: Small business concerns engaged in research and development activities within the health and life sciences sectors, aligning with NIH's mission. Confirm the full requirements in the official notice before applying.
NIH SBIR/STTR Omnibus Grant Solicitations (NCI) is funded by National Cancer Institute (NCI) (part of NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI SBIR/STTR Omnibus Grant Solicitations is sponsored by National Cancer Institute (NCI) (part of NIH). The NCI offers SBIR and STTR grant opportunities for small businesses engaged in research and development within the mission of the National Institutes of Health. NCI's research areas of interest include therapeutics, in vitro and in vivo diagnostics, imaging technologies, devices for cancer therapy, tools for cancer biology research, technologies and agents for cancer prevention, technologies for cancer control, and digital health.
NCI SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI) (part of NIH). This NOFO specifically solicits SBIR grant applications from small business concerns to support later-stage research and development (Phase IIB) for projects previously funded under SBIR or STTR Phase II awards from any federal agency.
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleThe April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read article